Myriad Genetics, Inc. (MYGN) Stock Grade

About Myriad Genetics, Inc.'s fundamentals

Myriad Genetics is a diagnostics and research company with a market capitalization of $400.5 million that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of -44.4%. The company experienced a slight revenue decline of 1.6% year-over-year, indicating contraction in its top-line performance. With no dividend yield and negative profitability metrics, the company is in a loss-making position and reinvesting or burning through capital rather than returning value to shareholders.